Generalizability of treatment outcome prediction in major depressive disorder using structural MRI: A NeuroPharm study

Vincent Beliveau*, Ella Hedeboe, Patrick M Fisher, Vibeke H Dam, Martin B Jørgensen, Vibe G Frokjaer, Gitte M Knudsen, Melanie Ganz

*Corresponding author af dette arbejde
3 Citationer (Scopus)


Brain morphology has been suggested to be predictive of drug treatment outcome in major depressive disorders (MDD). The current study aims at evaluating the performance of pretreatment structural brain magnetic resonance imaging (MRI) measures in predicting the outcome of a drug treatment of MDD in a large single-site cohort, and, importantly, to assess the generalizability of these findings in an independent cohort. The random forest, boosted trees, support vector machines and elastic net classifiers were evaluated in predicting treatment response and remission following an eight week drug treatment of MDD using structural brain measures derived with FastSurfer (FreeSurfer). Models were trained and tested within a nested cross-validation framework using the NeuroPharm dataset (n = 79, treatment: escitalopram); their generalizability was assessed using an independent clinical dataset, EMBARC (n = 64, treatment: sertraline). Prediction of antidepressant treatment response in the Neuropharm cohort was statistically significant for the random forest (p = 0.048), whereas none of the models could significantly predict remission. Furthermore, none of the models trained using the entire NeuroPharm dataset could significantly predict treatment outcome in the EMBARC dataset. Although our primary findings in the NeuroPharm cohort support some, but limited value in using pretreatment structural brain MRI to predict drug treatment outcome in MDD, the models did not generalize to an independent cohort suggesting limited clinical applicability. This study emphasizes the importance of assessing model generalizability for establishing clinical utility.

TidsskriftNeuroImage. Clinical
Sider (fra-til)1-9
Antal sider9
StatusUdgivet - jan. 2022


Dyk ned i forskningsemnerne om 'Generalizability of treatment outcome prediction in major depressive disorder using structural MRI: A NeuroPharm study'. Sammen danner de et unikt fingeraftryk.